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Abstract  
Introduction: There is a reasonable theoretical base for understanding the possible causes 
and motivation behind substance misuse and its dependency. There is a need for a reliable 
and valid measure that delineates the markers of substance use from its initiation, and 
identifies different motivations for drug use transitioning, maintenance and dependency. We 
addressed this gap in the UK by examining and validating the Substance Transitions in 
Addiction Rating Scale (STARS).  
Methods: 390 male prisoners were screened for conduct disorder and assessed with a clinical 
diagnostic interview for Attention deficit / hyperactivity disorder (ADHD). They completed 
the four STARS subscales regarding their substance use. Exploratory Structural Equation 
Modelling was performed to assess the STARS structure and to derive factors to assess 
validity against ADHD and conduct disorder diagnostic categories.  
Results: Each of the subscales produced meaningful and reliable factors, which supported the 
self-medication and behavioural disinhibition hypotheses of substance use motivation. The 
findings robustly show that ADHD is significantly associated with the need for coping as a 
way of managing primary and comorbid symptoms, but not conduct disorder. The findings 
were strongest for the combined ADHD type.  
Discussion: The STARS has a great potential to further the understanding of the motivation 
behind substance use and its dependency in different populations.  
Keywords: Drug dependence; motivations; ADHD; conduct disorder; transitions; self-
medication 
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Findings from the Bureau of Justice Statistics shows that approximately half of all prison 
inmates have a substance use disorder (Mumola & Karberg, 2006). Worldwide estimates of 
substance use disorders (SUD) in prisons have been reported as high as 48% (Fazel, Bains, & 
Doll, 2006). These figures are in contrast with estimates of the general population prevalence 
at 9.4% (Grant et al., 2004). SUD have high societal costs (Rice, 1999; Whiteford, Ferrari, 
Degenhardt, Feigin, & Vos, 2015), and the burden of disease is evidenced in higher rates of 
morbidity and mortality (Charlson et al., 2015), due to overdosing, high-risk behaviours and 
other causes (Binswanger et al., 2007). Untreated substance dependence also contributes to 
individuals engaging in drug-related crime, which in turn may lead to recidivism (Baillargeon 
et al., 2010). Furthermore, in the criminal justice setting, SUD are often accompanied by 
insalubrious practices that lead to blood-borne pathogen infections such as Hep C and HIV 
(Albizu-Garcia, Caraballo, Caraballo-Correa, Hernandez-Viver, & Roman-Badenas, 2012; 
Burt et al., 2007; Pena-Orellana, Hernandez-Viver, Caraballo-Correa, & Albizu-Garcia, 
2011).  
Substance misuse is linked with higher rates of co-existing psychiatric morbidity 
(Abram, Teplin, McClelland, & Dulcan, 2003). A meta-analysis demonstrated an increased 
likelihood of having SUD among prison inmates diagnosed with attention 
deficit/hyperactivity disorder (ADHD), with a joint prevalence estimate of this comorbidity at 
74% (Young et al., 2015). ADHD manifests as a combination of symptom clusters of 
inattention and hyperactivity/impulsivity, with onset prior to age 12 (APA, 2013). 
Considerable evidence from population surveys and follow-up studies indicates frequent co-
occurrence between ADHD and SUD (Biederman et al., 2006; van Emmerik-van 
Oortmerssen et al., 2012). A lifetime prevalence of 23% was recently reported based on 
international samples of treatment-seeking adults with SUD (van Emmerik-van Oortmerssen 
et al., 2014).  
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ADHD is widespread amongst incarcerated individuals. The estimated pooled 
prevalence of ADHD in prison ranges between 26-30% (Young, Moss, Sedgwick, Fridman, 
& Hodgkins, 2014), which substantially contrasts with prevalence estimates in the general 
population at about 2.8-5.3% (Polanczyk, de Lima, Horta, Biederman, & Rohde, 2007; 
Simon, Czobor, Balint, Meszaros, & Bitter, 2009). This dual-diagnosis has critical 
implications for intervention and policy, because ADHD is associated with further 
comorbidity (van Emmerik-van Oortmerssen et al., 2014), and moderates drug treatment 
outcomes with overall poorer prognosis (Levin et al., 2004). 
The motivation for substance utilization remains unclear. Findings from 
neurobiological sciences provide context to understand core processes in the development 
and maintenance of addiction (Grant, Brewer, & Potenza, 2006). Generally, findings indicate 
that repeated and chronic use of substances causes both anatomical and functional long-
standing brain alterations (Volkow & Li, 2005). Imaging studies demonstrate atypical 
markers in pre-frontal regions, and in their pathways to the basal ganglia-which collectively 
are known to be involved in dopaminergic circuitry (Wise, 2002). Dopaminergic activity is 
linked to reward circuits, which have been found in experimental tasks to represent processes 
of substance abuse and dependence in the form of impaired and impulsive decision-making 
abilities (Butner, 2011; Koob & Volkow, 2010; Urcelay & Dalley, 2012). Substance 
dependency also decreases sensitivity for the effects of rewards and affects, motivation and 
cognitive-control (Volkow et al., 2010), which may have implications for self-regulation. 
In the context of the reward systems hypothesis, several biopsychosocial explanations 
attempt to explain further the motivations and maintenance of SUD. The self-medication 
hypothesis generally refers to engaging in substance misuse in order to cope with the 
emotional burden of symptoms. As a neurobiological formulation, it indicates that 
individual’s recourse to substances that may aid compensation for deficiencies in the 
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dopamine system, thereby attempting to modulate emotional and behavioural processes via 
executive mechanisms of control (Silva et al., 2014). More generally this entails engaging in 
drug-taking behaviours as a way of coping with cognitive, psychological and emotional needs 
(Khantzian, 1985). Studies addressing this hypothesis have so far produced mixed results (for 
a review, see Young & Sedgwick, 2015). The behavioural disinhibition hypothesis refers to 
defective impulse control as the motivation underlying substance misuse. Reactive or rash 
disinhibition, as opposed to executive disinhibition, has been linked with SUD (Handley et 
al., 2011), and may be the by-product of reward sensitivity. This is exemplified by constant 
involvement in sensation/novelty-seeking behaviours (Faraone, Kunwar, Adamson, & 
Biederman, 2009). Impulsivity is widely thought to play an essential role in the initiation and 
development of habitual and problematic substance use (Gullo & Dawe, 2008). Meanwhile, 
the comorbidity hypothesis states that substance misuse is better explained by coexisting 
disorders with SUD (i.e., dual diagnoses), such as conduct disorder in youths, and personality 
traits, anxiety or mood disorders. A meta-analysis documented the extent of additional 
comorbidity present in patients with coexisting ADHD/SUD (van Emmerik-van Oortmerssen 
et al., 2014), lending some support to this view.  
The self-medication and behavioural disinhibition hypotheses may represent 
independent motivations for substance use maintenance. Meanwhile, substance misuse due to 
comorbidity (i.e. comorbid hypothesis) may be described by the presence of internalised 
disorders (such as stress reactions, anxiety and mood disorders), which are commonly found 
in ADHD (Young & Sedgwick, 2015). For instance, comorbid symptoms of stress, anxiety, 
depression and low self-worth are likely to be associated with self-medication but not with 
behavioural disinhibition for people with ADHD.  
These different explanatory models are helpful in providing a theoretical base for 
understanding the possible origins and motivations behind substance use and its dependency. 
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What is lacking in the literature is the availability of a reliable and valid measure that maps 
the transition of substance misuse based on motivations for use from its initiation, persistence 
and dependency. The current paper addresses this gap in the literature by validating a new 
instrument, the Substance Transitions in Addiction Rating Scale (STARS), as a measure of 
motivations, possible causes and transitions into addictive behaviours of psychoactive 
substances. The specific questions addressed were: a. Does the STARS have meaningful 
factors that are linked to theories of motivation for substance misuse? b. Does the STARS 
differentiate between subgroups that are understood to have different motivations for using 
substances?  
We therefore examined the factor structure and validity of the STARS’ four 
sequential substance use subscales from initial to continued drug use. In order to evaluate its 
utility in a clinical context, the magnitude of associations with ADHD and conduct disorder 
were estimated.  
Methods 
Participants and sample selection 
The sample was recruited by convenience sampling from Inverness Prison, Porterfield 
(Scotland, UK) over a period of 18 months. The sample was predominantly ‘White British’, 
with a mean age of 30.3 years. Out of the 96 (24.6%) prisoners who were diagnosed with 
ADHD in the current study, 15 (15.6%) reported having previously received pharmacological 
treatment for ADHD. Lifetime substance use endorsement in the sample was: alcohol 386 
(99.7%), heroin 175 (45.2%), cocaine 302 (78.0%), crack-cocaine 140 (36.2%), amphetamine 
286 (73.9%), cannabis 359 (92.8%) and ecstasy 304 (78.6%). Further details regarding 
sample selection and study procedures have been published elsewhere (Young et al., 2016).   
Participants were 390 male prisoners at Inverness Prison who completed the STARS. 
Their median incarceration time was approximately 4 months (0.33 years), with 43% 
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currently remanded. Analyses were then restricted to the 364 prisoners who endorsed 
substance use ever. The STARS is divided in four subscales (A, B, C, D) that refer to drug 
use onset, persistence, reason for transition or current preferred substance (full description 
below). In total 364 completed STARS A, 352 completed STARS B, 339 completed STARS 
C and 338 completed STARS D. Demographic characteristics and descriptive statistics of the 
study variables are presented in Table 1.  
-Insert Table 1 about here- 
Measures 
Substance Transition in Addiction Rating Scale(Young et al., 2016) 
The STARS was developed as a self-report measure to delineate a pathway of 
motivations for substance misuse from its initiation to the transitioning and persistence of 
psychoactive substances. The STARS consists of four scales based on a query regarding a 
specific substance: A. I first tried the drug because…(initiation, 18 items); B. I continued to 
use the drug because…(maintenance, 33 items); C. I moved on to other substances 
because…(transition, 21 items); D. I continued to take drugs because…(substance use 
maintenance, 33 items). Scale C has similar items to Scale A, plus three additional items 
addressing reasons for transitioning to other substances; Scales B and D have the same 33 
items. All item values range from 1 to 5. Individual STARS items are presented in Tables 3 
and 4.  
ADHD diagnosis and conduct disorder screening 
All participants were screened using the Barkley Adult ADHD Rating Scale-IV 
(BAARS-IV)(Barkley, 2011) and interviewed using the Diagnostic Interview for ADHD in 
Adults 2.0 (DIVA-2) (Kooij, 2010), which is a validated semi-structured clinical interview of 
ADHD in adults. The DIVA-2 is divided into categories of inattention and 
hyperactivity/impulsivity. Questions address their current and childhood (i.e. ages 5 to 12) 
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presentation of symptoms and inmates were classified according to DSM-5 criteria. Meeting 
the impairment criterion was required to establish ADHD diagnosis. 
Conduct disorder was screened using the conduct disorder scale of the BAARS-IV, 
which corresponds with DSM-5 criteria, with endorsement of three or more criteria indicating 
likelihood of the disorder. 
Procedures   
The researchers developed the conceptual work for the STARS items over a series of 
meetings. Items were generated in consultation with a working group with the purpose of 
developing a scale to delineate the motivations and pathways of drug use and its continuance. 
This included experts working in both addiction and forensic mental health services. The 
scale was piloted in six service users, drawn from addiction and forensic services at the South 
London and Maudsley NHS Trust (SLaM). Feedback was obtained from the service users 
that the STARS scales were acceptable to them, and feasible for use in complex services. 
Following the feedback, some of the items were simplified. No items were added or deleted. 
All aspects of the process and the development of the STARS scales were performed 
observing applicable standards for educational and psychological testing (American 
Educational Research Association, American Psychological Association, & National Council 
on Measurement in Education, 2014).  
The Scottish Prison Service approved this research study (reference: 7/13/10/10). 
Participants were informed about the study by flyers placed on noticeboards. Those who 
indicated interest attended an appointment with the researcher when they were given detailed 
written information about the study and the consent procedures. A comprehensive battery of 
measures was administered, including the BAARS-IV, the DIVA-2 and the STARS. Two 
researchers had previously attended comprehensive training sessions at the Maudsley 
Hospital Adult ADHD Service to reliably administer these measures.  
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Analytical strategy  
Frequencies were reported for all categorical variables, and means with their standard 
deviations for continuous descriptive variables. 
A factor analysis in the context of Exploratory Structural Equation Modelling (ESEM; 
Asparouhov & Muthén, 2009) was performed to assess the STARS structure and to derive 
factors to assess validity. The decision to perform exploratory work on the STARS using 
ESEM followed limitations identified for our purposes using traditional factor analyses. 
Firstly, considering the total number of items, our sample size limited our ability to perform a 
random split of the sample (50:50) to conduct separate Exploratory Factor Analysis (EFA) 
and Confirmatory Factor Analysis (CFA). Secondly, the use of CFA has the disadvantage 
that it requires robust measurement science that is often not available in clinical practice. In 
the context of examining a measure for the first time, searching for an acceptable 
measurement model may be better performed by EFA. Because we required standard errors 
for all factor loadings, indices of model fit indices, and being able to model the latent factors 
derived with covariates as part of the validation phase of the study, ESEM provided a better 
option.  
Model fit was assessed by the root mean square of approximation (RMSEA, with 
90% CI) and the Comparative-fit (CFI) and Tucker-Lewis (TLI) indices. Values of 0.06 or 
lower for RMSEA, and optimally above 0.95 for CFI and TLI indicate a very good model fit 
(Hu & Bentler, 1999; Yu & Muthén, 2002).  
Construct validity was assessed using a Multiple Indicators Multiple Causes model. In 
this procedure, the effects of a covariate (e.g. grouping variable, continuous score) on a 
measurement model are examined in order to establish whether groups based on the covariate 
have differential scores on the latent factors derived (Marsh, Morin, Parker, & Kaur, 2013). 
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Covariates used to correlate with ESEM-derived factors were age, ADHD and its categorical 
subtypes, and conduct disorder.  
Stata version 13 (StataCorp., 2013) was used for data management and descriptive 
analyses. Mplus version 7.1 (Muthén & Muthén, 2013) was used for all ESEM estimation. 
Results 
Model fit indices and the number of factors for each of the four STARS subscales is 
shown in Table 2. All indices of model fit are above the adequate thresholds for good fit, with 
the exception of the χ2 test, which is known to be an unreliable measure of model fit with 
large sample sizes (Bentler & Bonett, 1980). The STARS C (“I moved to other substances 
because…”) displays the best model fit of all STARS subscales (RMSEA 0.049 90% CI 
[0.040, 0.059], CFI 0.967, TLI 0.953). 
-Insert Table 2 about here- 
Table 3 shows the item loadings and factor solutions for the STARS A and C. STARS 
A (“I first tried the drug because…”) included two factors that were named Coping (10 
items) and Sensation-seeking (8 items). Examples of the highest loading items in the STARS 
A Factor 1- Coping include: (6) I thought it would help me sleep, (11) to help me cope with 
feelings of restlessness, and (16) to help me cope with stress. Example items for STARS A 
Factor 2- Sensation-seeking are: (9) Because of the sensation of it, and (8) Because people 
encouraged me to do so. Factor alphas (α) for the STARS A subscales were 0.811 and 0.711 
respectively. 
-Insert Table 3 about here- 
The STARS C (“I moved on to other substances because…”), had the same factors as 
STARS A, with an additional three items that directly addressed reasons for substance 
dependence transition (e.g. the drug I was taking wasn’t enough anymore). Results from the 
ESEM show a similar factor structure as the STARS A Factor 1 (i.e. Coping and Sensation-
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seeking), with the additional items generating a new factor that we named Dependency. 
Alpha (α) reliability coefficients for the three STARS C subscales were 0.800, 0.781 and 
0.750 respectively.  
Item loadings and factor solutions for the STARS scales B and D are presented in 
Table 4. The subscale B (“I continued to use the drug because…”) optimal solution derived 
four factors, namely Dependency (7 items, e.g. I couldn’t live without it), Sensation-seeking 
(9 items, e.g. If I didn’t take it I would lose my friends), Acceptance (5 items, e.g. I enjoyed 
taking it and didn’t want to give it up) and Coping (9 items, e.g. it helped me cope with daily 
life). Alpha (α) reliability indices for STARS B factors were 0.845, 0.717, 0.706 and 0.883 
respectively. 
-Insert Table 4 about here- 
Despite including the same items as STARS B, the factor configuration of STARS D 
(“I continued to take drugs because…”) differed slightly. The four STARS D factors were 
Dependency (14 items), Coping (4 items), Sensation-seeking (10 items) and Acceptance (3 
items), with alphas (α) of 0.921, 0.774, 0.813 and 0.634 respectively. 
-Insert Table 5 about here- 
Table 5 includes all results from the estimation of the effect of covariates on all 
STARS factors scores. For drug use initiation (STARS A), ADHD diagnosis was associated 
with higher scores on Coping and Sensation-seeking factors. In terms of substance use 
maintenance (STARS B), ADHD was associated with Coping but not with Sensation-seeking 
or Acceptance. On the drug transition scale (STARS C), ADHD was significantly associated 
with the Coping and the Dependency factors, but not with Sensation-seeking. For substance 
use maintenance, STARS D, ADHD was significantly associated with the Coping and 
Dependency factors. 
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After including conduct disorder on all models, the association between ADHD and 
the Sensation-seeking (STARS A) factor was attenuated, suggesting coexisting conduct 
disorder better explained this factor. We observed adjusted direct associations between 
conduct disorder with Sensation-seeking (STARS A), Acceptance (STARS B) and 
Dependency (STARS D) factors. 
ADHD subtype classification analyses show that associations between ADHD and 
factors were highest for the combined symptoms of inattention and hyperactivity-impulsivity 
type. Among this group, there were higher associations with Acceptance and Sensation-
seeking maintenance factors, on STARS B and D respectively. Among those with primary 
inattentive type, associations were restricted to Coping and Dependency on STARS C, and to 
Dependency in STARS D, whereas those with primary hyperactivity/impulsivity type did not 
have significant associations on any of the factors.  
Discussion 
This study set out to examine and validate the STARS as a measure of possible 
origins, motivations, and pathways into addictive behaviours of psychoactive substances. 
Construct and clinical validation was performed by examining associations with ADHD 
diagnosis, a neurodevelopmental disorder known to be a strong correlate and risk factor for 
SUD, after considering the potential influence of comorbid conduct disorder. Corresponding 
with ADHD diagnostic classifications, the STARS factors on the four subscales were 
analysed in terms of ADHD symptom dimensions of inattention, hyperactivity/impulsivity, 
and combined presentation.  
There were three key findings. First, exploratory work on the four STARS subscales 
produced a series of factors that were meaningful, reliable and consistent with existing 
theory. For example, the coping and behavioural disinhibition items loaded on separate 
factors. Secondly, there were subtle differences in the motivation for drug taking across 
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substance use initiation, maintenance of drug taking, and transition to other drugs. For 
example, the continuation of taking the initial drug was associated with psychological and 
physical dependence on the substance, which resulted in the need to try further drugs, leading 
in most instances to substance use maintenance. This suggests that it is important to look at 
each of the four sequential steps individually for clinical and research purposes.   
Thirdly, ADHD was significantly associated with the coping factor, which is 
consistent with the concept of self-medication, but also contained features of the comorbid 
hypothesis (e.g., managing stress, anxiety and mood). The findings were most robust for 
those with a diagnosis of the combined type, however, salient differences emerged between 
the primary inattentive and hyperactive/impulsive types. For example, the inattentive type 
had a much stronger need for a new drug during the substance use transition phase (i.e., 
“Because the drug I was taking wasn’t enough anymore”), and as a way of managing feelings 
of worthlessness, hopelessness and dependency during the substance use maintenance phase. 
This may be due to difficulties associated with inattention being more persistent than 
hyperactivity/impulsivity in adulthood. This differential in motivational effects by ADHD 
subtypes merits further research.   
To our knowledge, this is the first study to examine the self-medication hypothesis in 
the pathway to SUD among patients with ADHD using a reliable and operationalized 
definition of the construct. It was found that ADHD was linked primarily with factors 
representing self-medication, many of which indicated coexisting disorders, e.g. without it I 
felt hopeless about the future (depression), to help me cope with stress (stress/anxiety). Both 
depression and anxiety are two of the most frequent correlates with ADHD generally 
(Biederman et al., 2006; van Emmerik-van Oortmerssen et al., 2014) and in prison 
(Gonzalez, Velez-Pastrana, Ruiz Varcarcel, Levin, & Albizu-Garcia, 2015). In this context, 
further research should examine how much variance is explained by comorbid disorders, 
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using a structured approach and longitudinal-experimental designs that allow for testing 
moderators and mediators.  
Specific associations between ADHD and the STARS factors were partly determined 
by the stage of the transition. For instance, ADHD diagnosis was significantly associated 
with sensation-seeking traits but only in terms of substance use initiation. This suggests that 
sensation-seeking influences people with ADHD to try out drugs in the first instance, but it 
then ceases to be important and coping needs and dependency dominate the reason for 
continuing to use the first drug, trying out new drugs, and substance use maintenance. This 
could explain why the use of crack cocaine and heroin are so prominent among prisoners 
with ADHD (Young, Wells, & Gudjonsson, 2011). Nevertheless, consistent with previous 
research (Lynskey & Hall, 2001), our adjusted models revealed that any link between 
sensation-seeking items factors and ADHD was better explained by comorbid conduct 
disorder.  
Factor items are not identical across scales, nor do the factors labels mean that the 
factors represent only one construct. For instance, items related to social influences and peer 
pressure clearly loaded on the Sensation-seeking factors, suggesting that these processes are 
related. Also, the composition of the factors themselves changes along the transition in terms 
of drug misuse. Individuals who progress through substance misuse motivations that were 
related to coping become linked with dependency issues later on. This leads to the key 
message that if the progression from substance use initiation through the pathway is related to 
coping, rather than sensation-seeking (or peer-pressure), the risk for developing substance 
dependence may be higher.  
Limitations 
A key strength of the study is the sample size and a methodology in which every 
participant underwent a detailed diagnostic clinical interview of ADHD. However findings 
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may not be generalizable beyond the prison population, and although SUD in this context is 
exceedingly high, validation of the STARS scales is advised for other substance-dependent 
and clinical samples. The present study did not include females who may present as clinically 
distinct from community females, in terms of comorbidity, severity and impairment. When 
employing rating scales, limitations arise in relation to the subjectivity, reliability and 
accuracy of self reports, as well as the psychometric construction of the scales themselves 
(Naglieri & Goldstein, 2014). Finally, our cross-sectional design limits any causal 
interpretations of the association between ADHD and its symptoms and the STARS factor 
scores. 
Concluding remarks 
The present study shows that the STARS reliably measures different motivational 
factors involved in the path from initial drug taking to substance use maintenance. The 
STARS has great potential to further the understanding of the motivation behind substance 
use and its dependency among different populations for clinical and research purposes. In the 
current study, the findings clearly show that ADHD is significantly associated with the need 
for self-medication as a way of managing primary and comorbid symptoms. The findings 
were strongest for the combined ADHD type.  
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Table 1. Descriptive statistics and frequencies of Inverness (UK) prison sample 
 No %   No % 
STARS A 364 -  STARS C 339 - 
Age (yrs.)    Age (yrs.)   
  18-23  99 27.2    18-23  93 27.4 
  24-28  94 25.8    24-28  89 26.3 
  29-37  87 23.9    29-37  84 24.8 
  38-50  84 23.1    38-50  73 21.5 
  ADHD 92 25.3    ADHD 87 25.7 
  CD 151 41.5    CD 148 43.7 
       
STARS B 352 -  STARS D 338 - 
Age (yrs.)    Age (yrs.)   
  18-23  96 27.3    18-23  92 27.2 
  24-28  93 26.4    24-28  89 26.3 
  29-37  83 23.6    29-37  83 24.6 
  38-50  80 22.7    38-50  74 21.9 
  ADHD 92 26.1    ADHD 87 25.7 
  CD 151 42.9    CD 148 43.8 
Note: STARS-Substance Transition in Addiction Rating Scale, ADHD –  
Attention Deficit / Hyperactivity Disorder, CD-Conduct Disorder. 
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Table 2. Exploratory Structural Equation Model (ESEM) fit indices of STARS subscales 
Version No factors Chi sq. (df) RMSEA RMSEA 90%CI CFI TLI 
STARS A (18 items) 2 247.1 (118)* 0.055 [0.045, 0.064] 0.959 0.947 
STARS B (33 items) 4 766.4 (402)* 0.051 [0.045, 0.056] 0.967 0.957 
STARS C (21 items) 3 274.4 (150)* 0.049 [0.040, 0.059] 0.967 0.953 
STARS D (33 items) 4 837.4 (402)* 0.057 [0.051, 0.062] 0.963 0.952 
Note: RMSEA-Root Mean Square Approximation, CFI-Comparative Fit Index, TFI-Tucker-Lewis 
Index, STARS - Substance Transition in Addiction Rating Scale. 
*p < 0.001 
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Table 3. Item factor loadings and factor structure derived from exploratory structural equation modelling (ESEM) for STARS scales 
A (“I first tried the drug…) and C (“I moved to other substances…”). 
 A: Substance use initiation 
 (n = 364) 
C. Substance use transition (n = 339) 
Factor indicators F1 F2  F1 F2 F3 
1. Because I thought it would help me relax 0.685   0.784   
2. Because my friends were doing it  0.571   0.893  
3. Out of curiosity  0.527   0.843  
4. As a way of meeting new people  0.494   0.717  
5. Because I was bored  0.550   0.738  
6. Because I thought it would help me sleep 0.845   0.991   
7. As a way of 'forgetting' all my problems 0.726   0.62   
8. Because people encouraged me to do so  0.592   0.754  
9. Because of the sensation of it  0.679   0.752  
10. To help me lose weight 0.541   - - - 
11. To help me cope with feelings of restlessness 0.846   0.783   
12. Because I was feeling lonely 0.695   0.545   
13. To help me cope with schoolwork 0.718   0.621   
14. To help me cope with bullying 0.679   0.848   
15. Because my prescription was stopped 0.731   0.649   
16. To help me cope with stress 0.880   0.699   
17. Because the urge to do so was overpowering  0.454  - - - 
18. As a way of rebelling (e.g. from society, parents, 
authority)  0.629 
 
 0.501 
 
Items only in STARS C       
19. Because the drug I was taking wasn't enough 
anymore   
   
0.926 
20. Because I needed to seek a better high      0.687 
21. To cope with the effects of the first drug I took      0.571 
Factor α 0.811 0.711  0.800 0.781 0.750 
Note: STARS-Substance Transition in Addiction Rating Scale; STARS A, F1-Coping; F2-Sensation-seeking. STARS C, F1-
Coping; F2-Sensation-seeking; F3-Dependency 
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Table 4. Item factor loadings and factor structure derived from exploratory structural equation modelling (ESEM) for STARS scales B (“I continued 
to use the drug because…) and D (“I continued to take drugs because…”) 
 B. Substance use maintenance (n = 352)  D. Substance use maintenance (n = 338) 
Factor indicators F1 F2 F3 F4  F1 F2 F3 F4 
1. I couldn't stand the thought of stopping taking it 0.703     0.765    
2. I couldn't live without it 0.745     0.786    
3. If I didn't take it I would lose my friends  0.692      0.795  
4. It helped me feel comfortable in social situations    0.633   0.415   
5. It helped me to concentrate    0.665   0.519   
6. It was a good way of making new friends  0.551      0.774  
7. I didn't think taking drugs was bad for my health. - - - -     0.473 
8. It helped me cope with boredom.    0.397   0.431   
9. I didn't feel I had the mental strength to stop taking 
it 0.589    
 
0.724    
10. Without it I felt worthless 0.614     0.704    
11. It made me feel better about myself    0.558    0.525  
12. I felt under great pressure from friends to take it  0.628      0.809  
13. It helped me to calm down    0.708   0.562   
14. I enjoyed taking it and didn't want to give it up   0.777      0.641 
15. Without it I would have been 'nobody'  0.616      0.566  
16. Taking it was a part of my culture   0.471   - - - - 
17. It helped me maintain my weight loss  0.422    - - - - 
18. It had become an important part of my life   0.465   0.505    
19. It made me feel 'high'   0.446     0.513  
20. It gave me a feeling of confidence  0.445      0.641  
21. Without it I felt hopeless about the future - - - -  0.609    
22. It gave me energy  0.446      0.748  
23. I found it very exciting  0.564      0.792  
24. I saw no harm in taking it   0.549      0.608 
25. I felt physically unwell when I tried to stop 0.662     0.873    
Note: STARS-Substance Transition in Addiction Rating Scale; STARS B, F1-Dependency; F2-Sensation-seeking; F3-Acceptance; F4-Coping.  
STARS D, F1-Dependency; F2-Coping; F3- Sensation-seeking; F4-Acceptance. 
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Table 4 (cont.). Item factor loadings and factor structure derived from exploratory structural equation modelling (ESEM) for STARS scales B (“I 
continued to use the drug because…) and D (“I continued to take drugs because…”) 
 B. Substance use maintenance (n = 352)  D. Substance use maintenance (n = 338) 
Factor indicators F1 F2 F3 F4  F1 F2 F3 F4 
26. I wanted to reach new spiritual heights  0.502      0.440  
27. I was reminded of it by certain people and areas - - - -  0.505    
28. The urge to continue was overpowering 0.561     0.806    
29. Something bad happened in my life that led to my 
drug use getting out of control    0.632 
 
0.632    
30. It was a way to feel normal    0.685  0.801    
31. It was a way of forgetting all my problems    0.818  0.732    
32. It helped me to cope with daily life    0.848  0.884    
33. I tried to stop and failed 0.552     0.906    
Factor α 0.845 0.717 0.706 0.883  0.921 0.774 0.813 0.634 
Note: STARS-Substance Transition in Addiction Rating Scale; STARS B, F1-Dependency; F2-Sensation-seeking; F3-Acceptance; F4-Coping.  
STARS D, F1-Dependency; F2-Coping; F3- Sensation-seeking; F4-Acceptance. 
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Table 5. Construct validity of the STARS with demographics and ADHD diagnosis, categorical subtypes and dimensional symptom scores 
 STARS Factors 
 A: Substance use 
initiation 
B: Substance use maintenance C: Substance use transition D: Substance use maintenance 
Covariates  C SS D SS A C C SS D D C SS A 
ADHD onlya 0.483*** 0.323* 0.208 0.078 0.187 0.503*** 0.450** 0.255 0.484** 0.397** 0.410* 0.284 -0.088 
              
CD Adjusted 
modelb 
             
  ADHD + CD 0.530*** 0.206 0.217 0.050 0.034 0.427** 0.451** 0.217 0.406** 0.278* 0.322* 0.297 -0.068 
  CD -0.122 0.329* -0.014 0.055 0.467*** 0.238 -0.007 0.118 0.241 0.407** -0.138 0.309 -0.044 
              
ADHD 
dimensions 
             
  Primary I/A   0.382 0.361 0.252 0.043 0.010 0.320 0.469* 0.092 0.609* 0.464* 0.324 0.173 -0.324 
  Primary H/I  0.487 -0.049 0.367 -0.265 -0.259 0.339 0.263 -0.172 0.063 0.266 -0.006 0.092 -0.291 
  Combined  0.557** 0.400* 0.138 -0.215 0.425** 0.631*** 0.502** 0.470** 0.529** 0.426** 0.514** 0.401* 0.107 
Note: STARS-Substance Transition in Addiction Rating Scale; STARS A, C–Coping; SS-Sensation-seeking. STARS B, D–Dependency; SS-
Sensation-seeking; A-Acceptance; C–Coping. STARS C, C–Coping; SS-Sensation-seeking; D- Dependency. STARS D, D-Dependency; C-Coping; 
SS-Sensation-seeking; A-Acceptance. ADHD-Attention Deficit/Hyperactivity Disorder; I/A- Inattentive; H/I-Hyperactive-Impulsive; CD-Conduct 
Disorder 
aEstimates adjusted for age and every other symptom cluster type. 
bEstimates adjusted for age and include ADHD and conduct disorder simultaneously.  
***p < 0.001, **p < 0.01, *p < 0.05 
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Figure 1.  Empirically derived factors representing the paths through substance transition specific to ADHD, conduct disorder and in the general 
inmate sample 
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